Exact(8)
The usefulness of the genotype selection index (GSI) and the rank-sum (RS) procedures to identify stable and high-yielding genotypes were evaluated and then compared with the superiority (P) and reliability indexes (I .The association between yield variation and climatic factors as frosts, chilling, heat, rainfall and the interactions among them were also analyzed.
This met the trial's qualifications for non-inferiority (p < 0.001) but not for superiority (p = 0.08) [ 16].
This 12.5 % relative risk reduction with rivaroxaban met the criteria for non-inferiority (p < 0.001), but not superiority (p = 0.12).
The LSM treatment difference (220 mL, 95% CI 0.14 0.29) met the pre-defined criteria for superiority (p < 0.001).
As for Franklin, her "air of cool superiority" (p. 155) undermined Wilkins's self-confidence from the very beginning and this, in combination with his own "juvenile attitude towards women" (p. 133), ruled out "any romantic interest in Rosalind" (p. 133).
Similarly in SAVOR-TIMI 53, saxagliptin met the non-inferiority criterion but did not demonstrate cardiovascular superiority versus placebo (HR with saxagliptin 1.00, 95% CI 0.89 1.12, P = 0.99 for superiority, P < 0.001 for non-inferiority) [ 98].
Furthermore, higher-dose edoxaban demonstrated superiority (p = 0.02) to warfarin when the mITT population was analyzed, but this superiority was lost when the ITT population was tested (p = 0.08).
In the SAVOR-TIMI 53 trial [ 23], DPP4 inhibition with saxagliptin did not alter the rate of CV events (HR: 1.0; 95% CI: 0.89 to 1.12; P = 0.99 for superiority; P < 0.001 for noninferiority), although a higher heart failure hospitalization rate among saxagliptin users has been detected (HR: 1.27; 95% CI: 1.07 1.51; P = 0.007) during follow-up (median 2.1 years).
Related(1)
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com